NVO
Price
$56.11
Change
-$0.33 (-0.58%)
Updated
Aug 28 closing price
Capitalization
247.11B
68 days until earnings call
SLXN
Price
$7.74
Change
+$0.48 (+6.61%)
Updated
Aug 28 closing price
Capitalization
5.66M
Interact to see
Advertisement

NVO vs SLXN

Header iconNVO vs SLXN Comparison
Open Charts NVO vs SLXNBanner chart's image
Novo-Nordisk A/S
Price$56.11
Change-$0.33 (-0.58%)
Volume$9.54M
Capitalization247.11B
Silexion Therapeutics
Price$7.74
Change+$0.48 (+6.61%)
Volume$32.07K
Capitalization5.66M
NVO vs SLXN Comparison Chart in %
Loading...
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVO vs. SLXN commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVO is a Buy and SLXN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (NVO: $56.11 vs. SLXN: $7.74)
Brand notoriety: NVO and SLXN are both not notable
NVO represents the Pharmaceuticals: Major, while SLXN is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVO: 55% vs. SLXN: 35%
Market capitalization -- NVO: $247.11B vs. SLXN: $5.66M
NVO [@Pharmaceuticals: Major] is valued at $247.11B. SLXN’s [@Biotechnology] market capitalization is $5.66M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.17B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.99B. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVO’s FA Score shows that 1 FA rating(s) are green whileSLXN’s FA Score has 0 green FA rating(s).

  • NVO’s FA Score: 1 green, 4 red.
  • SLXN’s FA Score: 0 green, 5 red.
According to our system of comparison, NVO is a better buy in the long-term than SLXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVO’s TA Score shows that 4 TA indicator(s) are bullish while SLXN’s TA Score has 5 bullish TA indicator(s).

  • NVO’s TA Score: 4 bullish, 5 bearish.
  • SLXN’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SLXN is a better buy in the short-term than NVO.

Price Growth

NVO (@Pharmaceuticals: Major) experienced а +1.19% price change this week, while SLXN (@Biotechnology) price change was +13.75% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.18%. For the same industry, the average monthly price growth was +0.54%, and the average quarterly price growth was +11.97%.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.11%. For the same industry, the average monthly price growth was +20.33%, and the average quarterly price growth was +29.99%.

Reported Earning Dates

NVO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.18% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Biotechnology (+2.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVO($247B) has a higher market cap than SLXN($5.66M). NVO YTD gains are higher at: -32.972 vs. SLXN (-74.345). NVO has higher annual earnings (EBITDA): 154B vs. SLXN (-17.81M). NVO has higher revenues than SLXN: NVO (312B) vs SLXN (0).
NVOSLXNNVO / SLXN
Capitalization247B5.66M4,364,729%
EBITDA154B-17.81M-864,489%
Gain YTD-32.972-74.34544%
P/E Ratio14.42N/A-
Revenue312B0-
Total CashN/A3.47M-
Total DebtN/A3.7M-
FUNDAMENTALS RATINGS
NVO: Fundamental Ratings
NVO
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
PROFIT vs RISK RATING
1..100
78
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
90
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NVOSLXN
RSI
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 3 days ago
64%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
59%
Bearish Trend 1 day ago
10%
Momentum
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
27%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
30%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
27%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
66%
Bearish Trend 1 day ago
52%
Advances
ODDS (%)
Bullish Trend 8 days ago
67%
Bullish Trend 1 day ago
53%
Declines
ODDS (%)
Bearish Trend 4 days ago
59%
Bearish Trend 9 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
43%
Bullish Trend 5 days ago
38%
Aroon
ODDS (%)
Bearish Trend 3 days ago
55%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HLI200.740.47
+0.23%
Houlihan Lokey
EPAC42.880.09
+0.21%
Enerpac Tool Group Corp
GMRE7.38-0.16
-2.12%
Global Medical REIT
IBG0.58-0.03
-4.51%
Innovation Beverage Group Ltd
LPSN0.94-0.15
-13.41%
LivePerson

NVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVO has been closely correlated with NONOF. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVO jumps, then NONOF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVO
1D Price
Change %
NVO100%
-0.58%
NONOF - NVO
70%
Closely correlated
+1.93%
TECH - NVO
36%
Loosely correlated
-3.36%
GMAB - NVO
35%
Loosely correlated
+1.33%
BCAB - NVO
33%
Loosely correlated
-6.00%
MRK - NVO
32%
Poorly correlated
-1.02%
More

SLXN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLXN has been loosely correlated with IMA. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SLXN jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLXN
1D Price
Change %
SLXN100%
+6.54%
IMA - SLXN
63%
Loosely correlated
-1.32%
CELC - SLXN
50%
Loosely correlated
+9.29%
MRSN - SLXN
43%
Loosely correlated
+0.39%
CHRS - SLXN
26%
Poorly correlated
+3.51%
QSI - SLXN
25%
Poorly correlated
-0.86%
More